GSE209582 fluorouracil 1 v 0 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE209582_fluorouracil_1_v_0_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE209582_fluorouracil_1_v_0_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE209582_fluorouracil_1_v_0_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE209582_fluorouracil_1_v_0_human_up.

Results found

Linked to

 

Label

Description

 

Gene

THAP9 antisense RNA 1

Gene

non-coding RNA activated by DNA damage

Gene

long intergenic non-protein coding RNA 665

Gene

p53 upregulated regulator of p53 levels

Gene

long intergenic non-protein coding RNA 2593

Gene

interleukin 3 receptor subunit alpha

Gene

TMPO antisense RNA 1

Gene

MIR34A host gene

Gene

H2B clustered histone 20, pseudogene

Gene

transmembrane protein 198B (pseudogene)

  • Gene

    THAP9 antisense RNA 1


  • Gene

    non-coding RNA activated by DNA damage


  • Gene

    long intergenic non-protein coding RNA 665


  • Gene

    p53 upregulated regulator of p53 levels


  • Gene

    long intergenic non-protein coding RNA 2593


  • Gene

    interleukin 3 receptor subunit alpha


  • Gene

    TMPO antisense RNA 1



  • Gene

    H2B clustered histone 20, pseudogene


  • Gene

    transmembrane protein 198B (pseudogene)

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.